Glow-in-the-Dark tracer could reveal who responds to immunotherapy
NCT ID NCT05450484
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new imaging method to see a protein called PD-L1 in esophageal tumors. PD-L1 levels may help predict if immunotherapy will work, but current biopsy tests are often inaccurate. Researchers gave 21 patients a fluorescent tracer that binds to PD-L1, then used a special endoscope to measure the signal before and after standard cancer therapy. The goal was to see if the technique is safe and can show how PD-L1 expression varies within tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab-680LT (a fluorescent tracer)
What this could lead to
If successful, this imaging technique could help doctors see which patients might benefit from immunotherapy, leading to more personalized treatment for esophageal cancer.
What could go wrong
This is a very early, small study (21 people) focused on safety and feasibility, not on proving the technique improves outcomes. The tracer may not reliably predict treatment response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Medical Center Groningen
Groningen, 9713 GZ, Netherlands